 |
 |
Brian Collins <[log in to unmask]> wrote in part: <<The key point, which I missed out, is that new work that they have done shows that Selegiline is metabolised to des-methyl selegiline and this is what provides the protective component, but (and he is not very clear here ) It would appear that the remaining Selegiline masks the efect of the des-methyl selegiline. Does that make any more sense?>> The selegiline was not expected to provide symptomatic benefit during the early study. It was the anti-toxin (poisonous such as MPTP) effect that was sought. The MAO-B inhibiting by selegiline hydrochloride gives symptomatic benefit by preventing metabolic destruction of the dopamine that has carried the current (electron) across the synapse and become "loose" in the cerebral fluid. It seems that "des-methyl selegiline" counteracts toxic attack; ie., is the beneficial protective drug that may now be brought to market if their study continues to indicate that it is effective et c. -- Ron Vetter 1936, 1984 PD dz ... "money is coined liberty" ... Dostoevsky e-mail: [log in to unmask] http://www.ridgecrest.ca.us/~rfvetter